---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010095"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:31:46.312839+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma Q1 net loss $13.8M; cash $151.3M; pipeline prioritization extends runway into 2025

## Summary
- Net loss of $13.8M ($0.55 per share) vs $13.3M in Q1 2021; R&D $8.1M, G&A $5.7M.
- Cash and equivalents $151.3M, expected to fund operations into 2025 with three clinical readouts.
- IND opened for NASH Phase 2a trial of TERN-501 (mono + combo with TERN-101); top-line data expected H2 2023.
- TERN-601 (oral GLP-1) IND-enabling underway; Phase 1 for obesity expected in 2023.
- Partner Hansoh initiated Phase 1 trial of TERN-701 in CML in China; dosing underway.

## SEC filing metadata
- accession: 0000950170-22-010095
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017022010095/0000950170-22-010095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017022010095/tern-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010095
- JSON: https://secwatch.observer/filing/0000950170-22-010095.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.